Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Protagonist Therapeutics

    - PMLiVE

    J&J receives positive NICE recommendation for multiple myeloma treatment

    The treatment is approved for use within the NHS in England and Wales

    - PMLiVE

    Johnson & Jonson secures FDA approval for multiple myeloma treatment

    Support for first and only high-risk smouldering multiple myeloma treatment came from positive phase 3 trial results

    - PMLiVE

    Johnson & Johnson seeks first EMA approval for icotrokinra for plaque psoriasis

    Icotrokinra is a first-in-class, once-daily tablet for moderate-to-severe plaque psoriasis

    - PMLiVE

    John Morikis joins Johnson & Johnson’s board of directors

    Morikis was previously Chairman, President and CEO at Sherwin-Williams

    - PMLiVE

    Johnson & Johnson files FDA application for Tremfya in psoriatic arthritis

    Approximately 125 million people globally are living with some form of psoriasis

    - PMLiVE

    J&J announces EC approval of Imbruvica in previously untreated mantle cell lymphoma

    The drug is already approved in the EU to treat relapsed or refractory cases of the blood cancer

    - PMLiVE

    Johnson & Johnson’s Darzalex approved by EC as first treatment for high-risk SMM

    The early precursor of active multiple myeloma accounts for around 15% of all new multiple myeloma cases

    - PMLiVE

    Johnson & Johnson’s TAR-200 granted FDA priority review to treat bladder cancer

    An estimated 84,870 people will be diagnosed with bladder cancer in the US this year

    - PMLiVE

    J&J’s Darzalex recommended by CHMP to treat smouldering multiple myeloma

    If approved, Darzalex would be the first therapy approved in the EU for SMM

    - PMLiVE

    J&J’s Darzalex Faspro recommended by FDA panel of experts for smouldering multiple myeloma

    The early precursor of active multiple myeloma accounts for around 15% of all new cases

    - PMLiVE

    Johnson & Johnson’s bladder cancer therapy Balversa accepted by SMC

    Almost 1,700 people are diagnosed with bladder cancer in Scotland annually

    - PMLiVE

    J&J/Protagonist’s icotrokinra shows promise in difficult-to-treat plaque psoriasis

    An estimated eight million people in the US are living with the immune-mediated skin disease

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links